AEMD — Aethlon Medical Income Statement
0.000.00%
- $4.62m
- -$1.24m
- 17
- 45
- 13
- 13
Annual income statement for Aethlon Medical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.659 | 0.294 | 0.574 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.55 | 10.7 | 12.6 | 12.6 | 9.34 |
| Operating Profit | -7.89 | -10.4 | -12 | -12.6 | -9.34 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -522 | -565 | -463 | -389 | -85.8 |